We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Aalto Bio Launches New Recombinant Eukaryotic SARS-CoV-2, S1-S2 Spike Proteins for COVID-19 Testing

By HospiMedica International staff writers
Posted on 26 May 2020
Print article
Illustration
Illustration
Aalto Bio Reagents Ltd. (Dublin, Ireland) has launched its new range of recombinant SARS-CoV-2 spike (S) proteins for diagnostic test manufacturers, vaccine developers and researchers globally.

Among all structural proteins of SARS-CoV-2, the S protein is the main antigenic component that is responsible for inducing host immune responses and neutralizing antibodies. This makes it the principal focus of therapeutic and vaccine design for COVID-19. The S protein of SARS-CoV-2 is located on the surface of the viral particles and is comprised of two functional units, S1 and S2. The N-terminal S1 subunit is responsible for virus-receptor binding and the C-terminal S2 subunit mediates virus-cell membrane fusion. When used solely or in combination with our new insect-derived Nucleocapsid protein (N) (code BM 6424), our S1-S2 chimeric glycoprotein (code BM 6422) has demonstrated excellent reactivity in ELISA for detection of IgA, IgG and IgM antibodies against SARS-CoV-2.

"Patients continue to be screened for the virus by PCR on the front line," said Philip Noone, CEO of Aalto Bio Reagents, "however there is an important need for serological tests as well to detect all those mild or even asymptomatic cases that may otherwise be missed. Having diagnostic tests that can work in different healthcare settings will be the critical next step in battling this virus and crucial to their development is the selection of high-quality, raw materials used to design them. Our new S1, S2 glycoproteins and S1-S2 Chimeric proteins, in addition to our E. coli-derived N protein launched in February, have been rapidly developed to meet this urgent need."

Related Links:
Aalto Bio Reagents Ltd.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Computerized Spirometer
DatospirAira

Print article

Channels

Critical Care

view channel
Image: The potential for controlling diabetes with a single endoscopic treatment is spectacular (Photo courtesy of 123RF)

One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes

Over 37 million Americans are diagnosed with diabetes, and more than 90% of these cases are Type 2 diabetes. This form of diabetes is most commonly seen in individuals over 45, though an increasing number... Read more

Surgical Techniques

view channel
Image: The FieldForce Catheter is the first and only contact force PFA catheter optimized for the ventricles (Photo courtesy of Field Medical)

First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias

It is estimated that over 6 million patients in the US and Europe are affected by ventricular arrhythmias, which include conditions such as ventricular tachycardia (VT) and premature ventricular contractions (PVCs).... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more